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Insulin analogues play a key role in the effective management of type 2 diabetes. However, there are several behavioural barriers to appropriate early initiation of insulin therapy, despite compelling evidence supporting the benefits of this strategy in those patients for whom oral anti-diabetes agents provide insufficient control. The development of second-generation insulin analogues (insulin glargine 300 
U/mL and insulin degludec) has provided physicians with agents that can provide comparable glycaemic control to first-generation insulin, 
but with a reduced risk of hypoglycaemia and modes of action suited to once-daily regimens. These characteristics may help overcome 
patient and physician concerns about early insulin use in disease management. To date, there have been no head-to-head comparisons of 
second-generation insulins: here we consider recent real-world evidence and the forthcoming direct comparison in the BRIGHT randomised 
controlled study, as presented at the recent 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2018.
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Second-generation Basal Insulin Analogues in 
the Management of Type 2 Diabetes
Didac Mauricio 
Hospital de Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
The role of insulin in type 2 diabetes management and challenges 
to optimal initiation
Type 2 diabetes mellitus (T2DM) is a progressive disease, and many patients eventually require 
intensification of therapy from oral anti-diabetes agents. Basal insulin therapy is a cornerstone of 
T2DM management for patients who do not achieve glycaemic control following intensification of 
oral-therapy regimens.1,2 Insulin is an effective option for those with long-standing diabetes, and may 
be considered as a direct addition to metformin in patients with uncontrolled hyperglycaemia.1–6
However, there are psychological and behavioural considerations associated with insulin 
treatment – from both the perspective of the patient and of the physician – that may result in 
basal insulin therapy being frequently and inappropriately delayed.7 Patients often see insulin 
therapy as inconvenient, potentially painful, as a treatment of ‘last resort’ and an indication of 
failure to manage their disease.2,8 Physicians may be reticent to initiate the ‘final’ option of the 
recommended stepwise treatment algorithms, and typically share concerns with their patients 
over weight gain, burden of injections, and an increased risk of hypoglycaemia.1,2,8,9 Indeed, a recent 
large-scale (n=40,627) real-world study found that the majority of patients did not achieve a target 
glycated haemoglobin (HbA1c) of ≤7% in the first 3 months or after 2 years, following initiation of 
basal insulin treatment; the authors noted the role that treatment inertia might play in avoidable, 
inadequate glycaemic control.10 After initiation of basal insulin, delays in escalating titration (i.e. 
clinical inertia) have also been observed, contributing to suboptimal glycaemic control.11,12
Overcoming treatment inertia and appropriate insulin initiation
Patient concerns should be managed through education,8,13 which might include the benefits of 
glycaemic control, both in the short term and in terms of reduced complications in the longer 
term, and how appropriate insulin initiation using a personalised treatment approach can help 
achieve this.
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Physicians should consider that stepwise management algorithms 
typically wait for a treatment to be ineffective before escalation to, or 
addition of, another agent. This ‘wait for failure’ approach often means 
that patients may not be initiated on insulin therapy for relatively long 
periods of time,2,14,15 although current treatment recommendations from 
the American Diabetes Association and the European Association for the 
Study of Diabetes highlight that target achievement should be evaluated 
3 months after a change of treatment has been made.1,2 Suboptimal 
glycaemic control arising from treatment inertia has been observed in 
patients receiving oral anti-diabetes drugs (OADs), with notable delays 
in treatment escalation and a median of over 7 years before initiation of 
insulin treatment.15 In patients receiving three OADs, the probability of 
adding an OAD or initiation of insulin was 5.7% after 1 year (no patients 
received a fourth OAD), and mean HbA1c was 9.7% at the point of 
intensification to insulin.15
However, there exists compelling evidence to support a more active 
and target-driven approach, with long-term studies demonstrating the 
benefits of early target-driven treatment of hyperglycaemia in terms 
of reducing micro- and macro-vascular complications (Table 1).16,17 
Reductions in risk of microvascular disease, myocardial infarction and 
death achieved with a median of 10 years of intensive glycaemic control16 
were maintained during 10 years of post-trial follow-up.17 Treat-to-target 
management can be supported with a personalised treatment approach, 
using timely escalation through step-wise guidelines to achieve tight 
glycaemic control and reduce unnecessary glycaemic burden resulting 
from delayed or suboptimal intervention.2,14,15
Era of the second-generation basal insulin 
analogue
In recent years, significant advances have been made in basal insulin 
therapy. The second generation of basal insulin analogues offers 
compelling therapeutic benefits over first-generation insulin therapies, 
which may help physicians and patients overcome some of the barriers 
to initiation and intensification of insulin treatment.18–23
Second-generation basal insulin analogues (insulin glargine 300 U/
mL [Gla-300; Sanofi, Paris, France] and insulin degludec [IDeg; Novo 
Nordisk, Bagsværd, Denmark]) have demonstrated similar efficacy in 
reducing HbA1c to first-generation insulin therapy (e.g. insulin glargine 
100 U/mL [Gla-100; Sanofi]).18 However, the newer agents have longer 
and more stable pharmacokinetic (PK) and pharmacodynamic (PD) 
profiles than first-generation treatments.19–23 Gla-300 is associated 
with low within-day variability and high reproducibility (low between-
day variability) in insulin exposure,19,24 with predictable and stable 
glycaemic control well beyond 24 hours.25 Similarly, IDeg has 
demonstrated activity for up to 42 hours with four times lower day-
to-day within-patient variability in glucose reduction compared with 
Gla-100.20 A comparison of the steady state PK/PD profiles of Gla-
300 and IDeg revealed that Gla-300 provided 20% less within-day 
fluctuation of metabolic activity than IDeg over 24 hours at a dose of 
0.4 U/kg/day (Figure 1).26
These advances have translated into the clinically meaningful benefit 
of providing similar glycaemic control to Gla-100, but with an ultra-long 
duration (>24-hour coverage), a more stable PK profile (resulting in 
reduced glycaemic variability), and greater injection time flexibility. These 
factors make second-generation basal insulin analogues suitable for 
once-daily treatment.19–23
In addition to effectively reducing HbA1c, the second-generation basal 
insulin analogues are associated with a lower risk of hypoglycaemia 
(both nocturnal hypoglycaemia and also, for Gla-300, all-day 
hypoglycaemia) compared with Gla-100 (Figure 2).18,27,28 For Gla-300, the 
benefit of lower incidence of hypoglycaemia is especially pronounced 
in the titration period.29
Concluding remarks
The second-generation basal insulin analogues provide physicians 
with new treatment options for achieving targeted glycaemic control. 
While providing similar efficacy in lowering HbA1c to first-generation 
insulin analogues, the newer insulin treatment options provide 
additional clinical benefits, including a more stable, ultra-long duration 
of action that enables once-daily administration with flexibility in daily 
injection time, together with a lower risk of hypoglycaemia. ❒
Table 1: Long-term* benefits of reducing hyperglycaemia in 
patients with type 2 diabetes mellitus
Outcome Risk reduction for each 1% 
decrease in HbA1c over a 
median 10-year period
Death related to diabetes 21%
All-cause mortality 14%
Fatal and non-fatal myocardial infarction 14%
Fatal and non-fatal stroke 12%
Microvascular endpoints 37%
Cataract extractions 19%




*Median 10 years. HbA1c = glycated haemoglobin. Information source: Stratton et al., 
2000.16
Figure 1: Mean glucose infusion rate profiles of insulin 
glargine 300 U/mL and insulin degludec at the 0.4 U/kg/day 
dose level in steady state
CI = confidence interval; Gla-300 = insulin glargine 300 U/mL; IDeg = insulin degludec. 






























Treatment ratio (Gla-300/IDeg): 0.80 (90% CI: 0.66 to 0.96), p=0.047
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Figure 2: Meta-analysis assessment of the risk of nocturnal and anytime hypoglycaemia or severe hypoglycaemia with 
second-generation insulins compared with insulin glargine 100 U/mL
CI = confidence interval; Gla-100 = insulin glargine 100 U/mL; Gla-300 = insulin glargine 300 U/mL; h = hours; IDeg = insulin degludec; OD = once-daily; RR = relative risk.  
Reproduced under the CC-BY-NC license from Roussel et al., 2018.18
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BEGIN Basal-Bolus Type 2 0.99 (0.92 to 1.05)
Overall (anytime) 0.91 (0.92 to 1.03)
BEGIN Once Asia 0.94 (0.77 to 1.13)
BEGIN Flex (OD) 0.88 (0.72 to 1.07)
BEGIN Low Volume 0.93 (0.70 to 1.23)
BEGIN Once Long 1.00 (0.86 to 1.17)
Nocturnal (00:01–05:59 h)
BEGIN Basal-Bolus Type 2 0.84 (0.72 to 0.98)
Overall (nocturnal) 0.79 (0.66 to 0.94)
BEGIN Once Asia 0.85 (0.59 to 1.23)
BEGIN Flex (OD) 0.49 (0.31 to 0.77)
BEGIN Low Volume 0.70 (0.36 to 1.35)









EDITION 1 0.90 (0.77 to 1.04)
Overall (anytime) 0.81 (0.69 to 0.94)
EDITION JP 2 0.91 (0.52 to 1.58)
EDITION 3 0.61 (0.43 to 0.87)
EDITION 2 0.78 (0.63 to 0.95)
Nocturnal (00:00–05:59 h)
EDITION 1 0.76 (0.57 to 1.03)
Overall (nocturnal) 0.75 (0.61 to 0.92)
EDITION JP 2 1.00 (0.47 to 2.14)
EDITION 3 0.59 (0.33 to 1.06)
EDITION 2 0.75 (0.51 to 1.10)
Estimated RR
(95% CI)
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Second-generation basal insulin analogues – the 
story so far
Compared with first-generation basal insulin analogues, second-
generation treatments (insulin glargine 300 U/mL [Gla-300] and insulin 
degludec [IDeg]) have demonstrated improved pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles that provide greater glucose stability 
(less intra-day variation), together with a lower risk of hypoglycaemia, 
in patients with type 2 diabetes mellitus (T2DM).1–5 As a result, clinicians 
now have insulin treatment options that provide glycaemic control with 
the benefit of a stable, ultra-long duration of action that allows once-daily 
administration with flexibility in daily injection time. However, while the 
available evidence demonstrates that Gla-300 and IDeg provide similar 
clinical benefits to first-generation basal insulin analogues (albeit via 
different mechanisms of action),5–7 no direct comparison between the 
second-generation basal insulin analogues has been presented to date.
Emerging data from the 11th International 
Conference on Advanced Technologies & 
Treatments for Diabetes (ATTD)
Data from three studies of second-generation basal insulin analogues 
were presented at ATTD (Vienna, Austria) in February 2018. Real-world 
evidence from the DELIVER-D study8 was validated by a second real-
world study, LIGHTNING,9 which used a similar methodology applied 
to a larger source dataset of electronic medical records. In addition to 
the real-world studies, the BRIGHT study provides the first randomised 
controlled trial (RCT) evidence from a head-to-head comparison of 
second-generation basal insulin analogues.10
The most recent data from each of these three studies (DELIVER-D, 
LIGHTNING, BRIGHT) were presented at the ATTD 2018 meeting and are 
reviewed here.
Assessing comparative real-world findings 
in patients switching from first- to second-
generation basal insulin analogues
DELIVER-D
Previously published data from the EDITION and BEGIN clinical trials and 
subsequent meta-analyses have demonstrated consistent efficacy and 
improved safety profiles for second-generation basal insulin analogues 
(Gla-300 in EDITION and IDeg in BEGIN), compared with insulin glargine 
100 U/mL (Gla-100).5–7 However, the extent to which these findings from 
strictly controlled RCT settings are applicable to real-life practice has yet 
to be examined. In these initial trials, patients with hypoglycaemia were 
often excluded.5–7 In addition, no direct comparisons between Gla-300 
and IDeg have been presented to date.
DELIVER-D was a retrospective, observational study assessing safety 
and efficacy outcomes from electronic medical records in patients in 
the US switching from first-generation Gla-100 to either Gla-300 or IDeg. 
Head-to-head differences between the two second-generation basal 
insulin analogues were investigated.8 
DELIVER-D assessed data from the Predictive Health Intelligence 
Environment database, which covers 39 integrated US healthcare 
networks. Data were gathered for adult patients with T2DM who 
were switched from Gla-100 to either Gla-300, IDeg 100 U/mL or 
IDeg 200 U/mL (index date: first prescription date during the period 1st 
March 2015 to 31st December 2016) and who had at least one Gla-100 
prescription within 6 months before the index date (baseline period), 
but who had not received any other basal insulin prescriptions during this 
period. In order to be included in the study, patients were required to have 
electronic medical records for at least 12 months prior to, and at least 6 
months following the index date, and to have had at least one glycated 
haemoglobin (HbA1c) measurement during the 6-month baseline period.8
Patients who switched from Gla-100 to Gla-300 or IDeg were matched 
in a 1:1 ratio using a propensity score based on: baseline demographics 
(age, gender, race, insurance type, geographic region); their clinical 
characteristics 12 months prior to the index date (body mass index, 
Charlson comorbidity index score, prevalence of comorbidities, 
concomitant medication use); and their clinical characteristics within 
the 6-month baseline period (HbA1c, hypoglycaemia incidence, utilisation 
of all-cause health care). After propensity score matching, the Gla-
300 (n=810) and IDeg (n=810) cohorts were comparable in terms of 
demographics and baseline characteristics.8
The DELIVER-D study included endpoints in both the full matched cohorts 
and in a subgroup of patients with HbA1c measurements at both the 
6-month baseline and during 3–6 months of follow-up. In the matched 
cohorts, both the incidence of hypoglycaemia (identified by International 
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]/
International Classification of Diseases, 10th Revision, Clinical Modification 
[ICD-10-CM]) code and/or plasma glucose level ≤70 mg/dL [3.9 mmol/L]) 
and the event rate (events per patient per year [PPPY], adjusted for baseline 
hypoglycaemia event) during the 6-month follow-up period were assessed. 
In the subgroup, the endpoints examined were HbA1c reduction from 
baseline (closest to index date) at follow-up (latest available value during 
the follow-up period), and the proportion of patients attaining target HbA1c.8
Both Gla-300 and IDeg provided similar clinically meaningful decreases 
in HbA1c following switching (0.49% and 0.48% reductions in HbA1c, 
respectively) and enabled similar proportions of patients to achieve the 
target HbA1c of either <7.0% or <8.0% (12.9% versus 15.9% and 44.2% 
versus 44.6%, respectively). Following switching, patients on the second-
generation treatments experienced a lower incidence of hypoglycaemia 
versus baseline (Gla-300: 16.5 to 11.9%; IDeg: 15.4 to 12.7%); there was no 
significant difference between Gla-300 and IDeg when adjusted for baseline 
hypoglycaemia incidence (Figure 1). Both second-generation treatments 
provided similar reductions in the average number of hypoglycaemia 
events per year (least squares mean [LSM] difference in event rate -0.01 
events/PPPY, 95% confidence interval [CI] [-0.18, 0.15], p=0.88) and the rate 
of emergency visits or hospitalisations for hypoglycaemia (LSM difference 
in event rate -0.01 events/PPPY, 95% CI [-0.12, 0.09], p=0.82).
Until RCT data are available to support head-to-head comparisons, these 
data provide valuable insights into real-world outcomes and demonstrate 
the improved efficacy and safety profiles of modern second-generation 
basal insulin analogues in routine clinical practice.
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The LIGHTNING study assessed real-world efficacy and safety outcomes in 
patients with T2DM switching to first- (Gla-100 or insulin detemir [IDet]) or 
second-generation (Gla-300 or IDeg) basal insulin analogues. Preliminary 
results of an analysis of Humedica electronic health records – a database 
capturing data from over 5 million people with diabetes across more than 
50 US healthcare systems, 700 hospitals and 7,000 clinics – from 1st April 
2015 to 31st December 2016 – are presented here.9
The dataset included 779,813 people with T2DM receiving basal 
insulin analogues. A total of 130,155 basal insulin analogue treatments 
complied with the study inclusion criteria (Figure 2), representing 
patients either initiating a new basal insulin or switching between 
basal insulins. Patients were excluded from the study if they had a 
likely predominant diagnosis of type 1 diabetes, or if they had more 
than 10 basal insulin switches within the study window (as such cases 
would likely represent unusual clinical behaviour).9 Data presented 
here focus only on findings in patients switching between basal insulin 
treatment options.
The study approached its assessment using an analysis unit of ‘patient 
treatment’ – the period of time between treatment index (basal 
insulin initiation or switching event) and treatment end – and only 
counted on-treatment hypoglycaemic events during each patient-
treatment unit. Propensity score matching was used to match cohorts 
for potentially confounding characteristics, allowing for between-
treatment comparison. Key outcomes included the incidence of severe 
hypoglycaemia and HbA1c change from baseline in a subgroup of patients 
with HbA1c measurements in both time windows. Severe hypoglycaemia 
was defined as any hypoglycaemic event (ICD-9 or ICD-10 identified 
or plasma glucose ≤70 mg/dL [3.9 mmol/L]) related to an inpatient or 
emergency department encounter. HbA1c change was assessed as 
change from baseline to 76–180 days’ follow-up.9 
Switching from any basal insulin, patients who switched to Gla-300 had 
a significantly lower incidence of severe hypoglycaemia versus patients 
switched to the first-generation basal insulin analogues Gla-100 and IDet 
(p=0.009 and p=0.002, respectively). In the direct comparison between 
second-generation basal insulins, IDeg and Gla-300 provided similar 
reductions (p=0.370) in the rate of severe hypoglycaemia (Figure 3).9
Overall, results of the analysis showed that there was a similar reduction 
in HbA1c for patients switching to Gla-100, IDet and Gla-300, and similarly 
there was no significant difference between the second-generation 
treatments (Gla-300 and IDeg; p=0.591; Figure 4).9
Findings from this large, observational study of patients switching from 
any basal insulin to Gla-100, Gla-300, IDet or IDeg support the conclusions 
of DELIVER-D: that in real-world populations, second-generation basal 
insulin analogues provide similar efficacy and improved safety profiles 
versus first-generation agents. Both second-generation treatments 
(Gla-300 and IDeg) provided similar reductions in the rate of severe 
hypoglycaemia during a 6-month follow-up.9 
DELIVER-D and LIGHTNING – the limitations of  
real-world studies
Although these real-world studies provide valuable information about 
the use of second-generation basal insulins across a broad patient 
group, there are some limitations to consider. All patient medical records 
included in DELIVER-D and LIGHTNING came from the US; it would be 
valuable to also assess the benefits of new basal insulin analogues in 
a broader geographical population. Hypoglycaemia incidence was 
generally generated from hospital administration codes or laboratory 
glucose values, without data from self-measured blood glucose values 
or continuous blood glucose monitoring. In addition, there are no 
insulin titration data from these studies, making it difficult to compare 
or comment on the dosing regimens in patients switching basal insulin 
treatment. The follow-up period was relatively short at 6–12 months in 
the preliminary data presented at the ATTD 2018 meeting. Finally, as with 
any real-world study, it is difficult to confirm that the prescriptions for the 
treatments were filled and used appropriately.
The first randomised, controlled head-to-head 
comparison of second-generation basal insulin 
analogues
BRIGHT
Recent real-world observations have shown that switching from Gla-100 
to either Gla-300 or IDeg resulted in similar improvements in terms of 
hypoglycaemia risk during the whole follow-up period. Rates of severe 
hypoglycaemia were similar for the second-generation treatments 
and significantly lower than first-generation basal insulins, without 
compromising efficacy in HbA1c reduction.8,9 
However, despite the valuable insights obtained from real-world 
assessments, PK and PD data, and meta-analyses, there has been an 
absence of RCT head-to-head comparisons of second-generation basal 
insulin analogues. Such data from randomised controlled studies could 
help to inform and support optimal treatment selection in T2DM.
The BRIGHT study was a phase IV, 24-week, multinational, multicentre, 
open-label, two-arm, parallel-group trial (NCT02738151), including 
insulin-naïve adults with T2DM inadequately controlled with oral anti-
hyperglycaemic drugs, with or without a glucagon-like peptide-1 receptor 
agonist (Figure 5).10 Patients were randomised 1:1 to receive Gla-300 
(0.2 U/kg) or IDeg (10 U), administered once-daily using similar treat-to-
target titration protocols. 
The primary endpoint was HbA1c change from baseline to Week 24; 
both the non-inferiority and then superiority of Gla-300 versus IDeg 
were assessed. Secondary endpoints included the incidence and event 
rates of hypoglycaemia, blood glucose level changes, variability of 
Figure 1: Incidence of hypoglycaemia during 6-month 
follow-up in DELIVER-Da
aIncidence reduction from baseline to follow-up: Gla-300, p<0.01; IDeg, p=0.05.  
bAdjusted for baseline hypoglycaemia incidence. Gla-300 = insulin glargine 300 U/mL; 
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pre-breakfast glucose and adverse events.10 The study also included 
patient-reported outcomes as assessed by the Diabetes Treatment 
Satisfaction Questionnaire (DTSQ) and the Hypoglycaemia Attitudes and 
Behaviour Scale (HABS).11,12
At ATTD 2018, study demographics were presented for the BRIGHT study 
and are summarised here. Overall, 929 participants from 16 countries 
were randomised to Gla-300 or IDeg and 94% of participants completed 
the 24-week treatment period (Figure 6).10 Baseline characteristics were 
well-balanced between the two treatment cohorts, with an average age 
of 60 years, a baseline HbA1c of 8.6–8.7% and around half of patients 
having previously used more than two non-insulin glycaemic control 
drugs (Table 1).10
Both treatment groups used the same weekly insulin titration schedule 
with a target fasting plasma glucose (self-monitored) of 80–100 mg/
dL (4.4–5.6 mmol/L) without hypoglycaemia. The preliminary study 
data suggest a successful titration, with 47% of participants having 
reached the target HbA1c of <7.0% using a starting dose of 0.19 U/kg 
for Gla-300 and 0.12 U/kg for IDeg, as per label instructions. No specific 
Figure 2: LIGHTNING study population, including inclusion criteria
aMultiple treatments defined as those that have another treatment start within 1 week (before or after) of starting the specified basal insulin; binactivity defined as the lack of any 
time-stamped data. BI = basal insulin; Gla-100 = insulin glargine 100 U/mL; Gla-300 = insulin glargine 300 U/mL; HbA1c = glycated haemoglobin; IDeg = insulin degludec;  
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Participant age ≥18 years at rst known prescription of BI
No inactivity >270 days in the 365 days prior to index dateb
With baseline HbA1c values
Without multiple BIsa
Started after 1 April 2015
<10 BI switches within study window
Using Gla-100, IDet, IDeg or Gla-300















BI treatments included in the analysis
Figure 3: Rates of severe hypoglycaemia following a switch 
to insulin glargine 300 U/mL compared with a switch to 
other basal insulin analogues
Figure 4: HbA1c reduction following a switch to insulin 
glargine 300 U/mL compared with a switch to other basal 
insulin analogues
Gla-100 = insulin glargine 100 U/mL; Gla-300 = insulin glargine 300 U/mL; IDeg = insulin 
degludec; IDet = insulin detemir; PSM = propensity score matching; SE = standard 
error. Reproduced with permission from: Meneghini et al.9
Gla-100 = insulin glargine 100 U/mL; Gla-300 = insulin glargine 300 U/mL;  
HbA1c = glycated haemoglobin; IDeg = insulin degludec; IDet = insulin detemir;  
PSM = propensity score matching; SE = standard error.  Reproduced with permission 
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safety concerns were noted (Table 2). A similar proportion of patients in 
each treatment arm experienced treatment-related adverse events, with 
few serious events (less than 5% in each arm) and only around 1% of 
patients discontinuing treatment because of adverse effects.10 
We await with interest further details on results from the BRIGHT study, 
comparing second-generation insulins in a head-to-head context.
Discussion
With the availability of second-generation basal insulin analogues, 
clinicians now have ultra-long acting, efficacious treatment options with 
a low associated risk of hypoglycaemia.
Selection of a treatment for the personalised management of diabetes 
should be supported by data in relevant patient populations: here we have 
discussed both real-world data and clinical observations to supplement 
existing evidence from phase III RCTs and meta-analyses for Gla-300. 
DELIVER-D demonstrated that switching from Gla-100 to Gla-300 or IDeg 
provides similar glucose-lowering efficacy and reductions in hypoglycaemia 
risk between the second-generation insulins. LIGHTNING supported these 
findings, reporting a similar incidence of severe hypoglycaemia for Gla-
300 and IDeg, but lower than first-generation basal insulins, while retaining 
efficacy in HbA1c reduction.
Figure 5: BRIGHT study design and inclusion criteria
aWith the exception of a maximum of 8 consecutive days or 15 days total prior insulin use. BMI = body mass index; Gla-300 = insulin glargine 300 U/mL; IDeg = insulin degludec; 
GLP-1 RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; OAD = oral antihyperglycemic drug; SU = sulfonylureas; T2DM = type 2 diabetes mellitus.  





• T2DM duration ≥1 year
• HbA1c ≥7.5 to ≤10.5% at screening
• BMI ≥25 to ≤40 kg/m2
• OAD use ± GLP-1 RAs at stable dose
 for ≥3 months


















Figure 6: Patient randomisation in the BRIGHT study and 
overall completion data
AE = adverse event; Gla-300 = insulin glargine 300 U/mL; IDeg = insulin degludec.  











• 4 AE (0.9%)
• 4 poor compliance to
 protocol (0.9%)









• 5 AE (1.1%)
• 1 hypoglycaemia (0.2%)
• 3 poor compliance to
 protocol (0.6%)
• 21 other (4.5%)
IDeg
n=463





Age, years 60.6 ± 9.6 60.5 ± 9.8
Sex (male/female), n (%) 247/219 (53.0/47.0) 252/211 (54.4/45.6)
BMI, kg/m2 31.7 ± 4.3 31.3 ± 4.4
HbA1c, % 8.71 ± 0.83 8.57 ± 0.80
Known T2DM duration, years 10.5 ± 6.1 10.7 ± 6.5
Number of prior non-insulin 














Randomised population. Data expressed as mean ± SD unless stated otherwise.  
BMI = body mass index; Gla-300 = insulin glargine 300 U/mL; HbA1c = glycated 
haemoglobin; IDeg = insulin degludec; SD = standard deviation; T2DM = type 2 
diabetes mellitus. Reproduced with permission from: Cheng et al., 2018.10
Table 2: Preliminary safety data from the BRIGHT study




Participants with any TEAE 202 (43.7) 221 (47.8)
Participants with any TE SAE 21 (4.5) 20 (4.3)
Participants with any TEAE leading to death 1 (0.2) 0 (0.0)
Participants with any TEAE leading to 
permanent treatment discontinuation
4 (0.9) 5 (1.1)
Gla-300 = insulin glargine 300 U/mL; IDeg = insulin degludec; SAE = serious adverse 
event; TE = treatment-emergent; TEAE = treatment-emergent adverse event.  
Reproduced with permission from: Cheng et al., 2018.10
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Early demographic data from the head-to-head BRIGHT study show that 
it is well positioned, in terms of patient selection, randomisation and 
appropriate titration, to deliver meaningful insights into T2DM treatment 
selection when further data are released.
Together, data from both RCTs and real-world studies provide physicians 
with robust evidence for the clinical benefits of second-generation basal 
insulin analogues and support informed decisions when initiating and 
intensifying basal insulin therapy. ❒
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